Compare GTN & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | VSTM |
|---|---|---|
| Founded | 1897 | 2010 |
| Country | United States | United States |
| Employees | 9582 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.1M | 470.7M |
| IPO Year | N/A | 2011 |
| Metric | GTN | VSTM |
|---|---|---|
| Price | $4.50 | $5.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $8.50 | ★ $15.25 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.27% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $13.89 | $282.16 |
| Revenue Next Year | N/A | $72.63 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $3.13 | $4.01 |
| 52 Week High | $6.31 | $11.25 |
| Indicator | GTN | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 49.94 |
| Support Level | $4.27 | $5.56 |
| Resistance Level | $5.10 | $6.79 |
| Average True Range (ATR) | 0.23 | 0.41 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 42.07 | 71.06 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.